drugset / Trial / NCT01059422
Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients
Phase 4
Completed
10 enrolled
Central Institute of Epidemiology, Moscow, Russia
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will investigate whether combination antiretroviral therapy of raltegravir and 3TC/ABC is effective and safe to use in tuberculosis (TB)/HIV co-infected adults receiving rifabutin-containing, first-line antituberculous treatment. Hypothesis:Combination antiretroviral therapy of raltegravir and 3TC/ABC and is effective and safe to use in tuberculosis (TB)/HIV co-infected adults receiving rifabutin-based first-line antituberculous treatment.
Timeline
- Start
- 2010-10
- Primary completion
- 2013-03
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | 600 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |
| Subject | Raltegravir | Other / unclassified | 400 mg | — |